title: The value of estimating serum aproptotic marker concentrations in monitoring and prognosis of 131I--therapy in Graves' disease. Preliminary report.
abstract: BACKGROUND
  The effect of radioiodine (131I) in Graves' disease (GD) is probably due to the direct physical destruction of thyrocytes by beta radiation, and by the indirect action through stimulation of apoptosis in these cells. The aim of our study was to investigate the changes in serum concentrations of sFas and sFasL as stimulators of apoptosis, and Bcl-2 as an inhibitor of apoptosis in patients with GD following 131I administration.
  
  
  METHODS
  The study was performed on 30 patients with GD (29 female and 1 male aged 25-45). All patients were euthyroid (biochemical and clinical) prior to radioiodine therapy. The target absorbed dose ranged between 90 and 160 Gy. We assessed markers of apoptosis and hormone concentrations (fT3, fT4 and TSH) in the following manner: before 131I administration, then two weeks, one month, two, three, four, and five months after 131I administration.
  
  
  RESULTS
  After four months, the concentrations of sFas and sFasL rose by 50% and decreased during the next month. Pretherapeutic concentrations of Bcl-2 were elevated, and peaked two weeks after ingestion, showing a gradual decrease with time. We found a significant increase in serum TSH, and a decrease of fT3 and fT4 concentrations by the end of the third month of radioiodine therapy.
  
  
  CONCLUSIONS
  Decreases in serum levels of sFas and sFasL and increases of Bcl-2 are regarded as characteristic for GD patients before radioiodine therapy. Radioiodine therapy reverses the ratio of estimated markers after four months. The concentrations of hormones reflect actual thyroid function, whereas concentrations of markers of apoptosis may suggest morphological changes.
authors.affiliation: Department of Nuclear Medicine, Medical University of Białystok, Poland. rogowski@pb.bialystock.pl
authors.forename: Franciszek
authors.initials: F
authors.lastname: Rogowski
authors.forename: Adam
authors.initials: A
authors.lastname: Parfieńczyk
authors.forename: Antoni
authors.initials: A
authors.lastname: Sopotyk
authors.forename: Tadeusz
authors.initials: T
authors.lastname: Budlewski
authors.forename: Ewa
authors.initials: E
authors.lastname: Jabłońska
authors.forename: Beata
authors.initials: B
authors.lastname: Kiersnowska-Rogowska
authors.forename: Piotr
authors.initials: P
authors.lastname: Szumowski
mesh_terms: D000328:Adult; D017209:Apoptosis; D015415:Biomarkers / Q000097:blood; D001798:Blood Proteins / Q000032:analysis; D053222:Fas Ligand Protein; D005260:Female; D006111:Graves Disease / Q000097:blood* / Q000175:diagnosis / Q000532:radiotherapy*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood*; D008875:Middle Aged; D010865:Pilot Projects; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000097:blood*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D019014:fas Receptor / Q000097:blood*
chemical_list: D015415:Biomarkers; D001798:Blood Proteins; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D007457:Iodine Radioisotopes; D008562:Membrane Glycoproteins; D019253:Proto-Oncogene Proteins c-bcl-2; D019275:Radiopharmaceuticals; D019014:fas Receptor